PDS Biotechnology
PDSB
57 hedge funds and large institutions have $141M invested in PDS Biotechnology in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 5 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
4% more funds holding
Funds holding: 55 → 57 (+2)
0.07% less ownership
Funds ownership: 2.51% → 2.44% (-0.07%)
15% less capital invested
Capital invested by funds: $166M → $141M (-$25M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.76M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$672K |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$363K |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$318K |
| 5 |
State Street
Boston,
Massachusetts
|
+$165K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.11M |
| 2 |
VMI
VHCP Management II
New York
|
-$3.06M |
| 3 |
Millennium Management
New York
|
-$430K |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$335K |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$247K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $10K | +$9.66K | +48 | +1,600% |
|
|
SO
52
STRS Ohio
Columbus,
Ohio
| $9K | – | – | – |
|
53
Bank of Montreal
Toronto,
Ontario, Canada
| $9K | +$10.1K | +50 | New |
|
|
AIM
54
Advantage Investment Management
Cedar Rapids,
Iowa
| $8K | – | – | – |
|
55
UBS Group
Zurich,
Switzerland
| $8K | +$2.42K | +12 | +36% |
|
|
MAM
56
Meeder Asset Management
Dublin,
Ohio
| $3K | +$604 | +3 | +23% |
|
|
LTFS
57
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | +$2.62K | +13 | New |
|
|
58
AllianceBernstein
Nashville,
Tennessee
| – | -$335K | -1,560 | Closed |
|
|
VF
59
Virtu Financial
New York
| – | -$177K | -827 | Closed |
|
|
CS
60
Credit Suisse
Zurich,
Switzerland
| – | -$146K | -679 | Closed |
|
61
Russell Investments Group
London,
United Kingdom
| – | -$128K | -598 | Closed |
|
|
NFA
62
Nationwide Fund Advisors
Columbus,
Ohio
| – | -$99K | -463 | Closed |
|
PDSB Hedge Fund Activity: Q4 2017 in Review
57 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2017, worth a combined $141M — down 15% from $166M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PDSB positions and 5 closed out — a net gain of 2 holders — while 20 added to existing stakes and 14 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.76M. The largest seller was Acuta Capital Partners, cutting an estimated $3.11M.
- 57 institutional investors held PDS Biotechnology (PDSB) as of Q4 2017, up from 55 in Q3 2017.
- Funds reported $141M of PDS Biotechnology stock for Q4 2017, down 15% quarter-over-quarter.
- 7 funds opened new PDS Biotechnology positions in Q4 2017 and 5 closed out, a net change of +2 holders.
- The largest PDS Biotechnology buyer in Q4 2017 was Adage Capital Partners, an estimated $1.76M added.
- The largest PDS Biotechnology seller in Q4 2017 was Acuta Capital Partners, an estimated $3.11M sold.
Based on aggregated 13F filings for Q4 2017.